MGX NASDAQ
Metagenomi, Inc. Common Stock
1W: -11.3%
1M: -12.1%
3M: -18.4%
YTD: -38.9%
1Y: -57.3%
$1.02
-0.09 (-7.69%)
Weekly Expected Move ±6.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2025-03-17
Earliest Filing
2025-10-01
Latest Filing
partner: 3
Counterparties (Filed by MGX)
3 relationshipsCompanies named in MGX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Acuitas Therapeutics, Inc. | ACUT | partner | Metagenomi entered into a non-exclusive license agreement for Acuitas lipid nanoparticle technology. | 2025-10-01 | View |
| Affini-T Therapeutics, Inc. | — | partner | Metagenomi terminated its development and license agreement with Affini-T due to Affini-T's bankruptcy. | 2025-10-01 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Open Market Sale Agreement | 2025-03-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-22 | Regulation FD; Exhibits | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-06-10 | Officer/Director Change; Shareholder Vote | View | |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Amendments to Articles of Incorporation or Bylaws; Regulation FD Disclosure; Financial Statements an | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-01 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement | Agreement | View |
| 2025-08-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-11 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-14 | Other Events | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-17 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-17 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-01-16 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-12-10 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-03 | Other Events; Financial Statements and Exhibits | View | |
| 2024-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-05-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-05-01 | Termination of Material Definitive Agreement; Results of Operations and Financial Condition; Regulat | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR